NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
RADNOR, Pa., Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter and year to date 2024 financial results after the market closes on Wednesday, August 14, 2024, via press release, which will be available on the Company's website at . The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.
NRx製藥公司（納斯達克：NRXP）於2024年8月14日週三股市收盤後通過新聞稿公佈其2024年第二季度和截至當年日期的財務業績，該新聞稿將在公司網站上公佈。 該公司將於當天下午4:30 ET召開電話會議，討論財務業績以及提供公司的最新動態。
A live webcast of the conference call will be available on the Company's website at . Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
該電話會議的現場網絡直播將在公司網站上提供。無法加入網絡直播的參與者可以通過電話加入會議，國內撥打+1-800-717-1738，國際撥打+1-646-307-1865。
About NRx Pharmaceuticals, Inc.
關於NRx製藥公司
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx製藥公司是一家臨床階段的生物製藥公司，利用其NMDA技術平台開發治療中樞神經系統疾病的藥物，包括自殺性雙相情感障礙、慢性疼痛和創傷後應激障礙。該公司正在開發NRX-101，FDA指定的自殺性治療難以耐受的雙相情感障礙和慢性疼痛的突破性療法，計劃在患有雙相情感障礙、自殺傾向或坐立不安症狀的患者中提交加速批准藥品申請(NDA)。NRX-101有望成爲慢性疼痛的非阿片類治療，並可用於複雜的尿路感染的治療。
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx製藥公司最近宣佈，基於美國國立衛生研究院(nih)的嚴格臨床試驗結果和法國衛生管理局的新數據共享協議，正計劃提交一項關於NRX-100（IV胡椒酮）治療自殺性抑鬱症的新藥申請。NRX製藥公司獲得美國FDA提供NRX-100開發快速通道的認可，作爲治療急性自殺的一部分。
About HOPE Therapeutics, Inc.
關於HOPE Therapeutics，Inc.
HOPE Therapeutics, Inc. () is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
HOPE Therapeutics, Inc.（）是一家醫療服務公司，開發了一系列最佳臨床實踐網絡診所，爲患有自殺性抑鬱症及相關疾病的患者提供胡椒酮等 lifesaving therapies，該公司的數字治療平台是爲了增強和保留NMDA-targeted藥物療法的臨床效益而設計的。
SOURCE NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc.消息來源